Skip to main content
. Author manuscript; available in PMC: 2010 Mar 17.
Published in final edited form as: Cancer Res. 2007 May 15;67(10):4759–4766. doi: 10.1158/0008-5472.CAN-06-4246

Figure 5.

Figure 5

Rap1 reverts the T4-2 malignant phenotype through different signaling pathways from those targeted by EGFR or β1-integrin. Activity and expression of the components of (A) EGFR-MAPK and (B) PTEN/Akt pathways were examined by Western blotting. C, the levels of FOXO1 protein and mRNA were determined by Western and reverse transcription-PCR analyses, respectively.